Mark A. Lewis, MD

Mark A. Lewis, MD, is the director of GI oncology at Intermountain Health.

Articles

Mark A. Lewis, MD, with the Oncology Brothers presenting slides

Recent Data from COMMIT in dMMR/MSI-High Metastatic Colorectal Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

June 24th 2024

Mark A. Lewis, MD, discusses recent data from the COMMIT trial investing first-line treatment of patients with deficient DNA mismatch repair or microsatellite instability–high metastatic colorectal cancer.

COLLISION: Surgery vs Thermal Ablation for Small-Size Colorectal Liver Mets

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

June 24th 2024

The Oncology Brothers and Mark A. Lewis, MD, review recent updates from the COLLISION study that were presented at the 2024 ASCO Annual Meeting.

TRANSMET: Chemotherapy Plus Liver Transplant in Unresectable Colorectal Liver Metastases

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

June 24th 2024

Medical oncologists review recent data from the TRANSMET study evaluating chemotherapy plus liver transplantation in patients with unresectable colorectal liver metastases.

Key Updates from ARMANI in Advanced HER2- Gastric/GEJ Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

June 24th 2024

Mark A. Lewis, MD, and the Oncology Brothers discuss recent updates from the ARMANI trial in HER2- gastric/ gastroesophageal junction cancer.

Recent Updates from the ESOPEC Trial in Esophageal Adenocarcinoma

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

June 24th 2024

Following ASCO 2024, Mark A. Lewis, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide comprehensive insights on recent updates from the ESOPEC trial in esophageal adenocarcinoma.